Related Experiment Video
Updated: Jul 12, 2026
10:28
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
PET-CT in clinical oncology
A Maldonado1, F J González-Alenda, M Alonso
1Centro PET Recoletas La Milagrosa, Madrid, Spain. antonio.maldonado@gruporecoletas.com
Summary
Positron emission tomography/computed tomography (PET/CT) with 18F-FDG is a crucial tool for cancer management, offering metabolic insights beyond anatomy. This combined imaging modality significantly impacts patient care across various tumor types.
Area of Science:
- Oncology
- Medical Imaging
- Nuclear Medicine
Background:
- Anatomic imaging (CT, MRI) has long been used in oncology.
- Positron Emission Tomography (PET) revolutionized early cancer diagnosis by assessing tumor metabolism.
- PET/CT combines anatomic and metabolic imaging, becoming a vital tool in cancer patient management.
Purpose of the Study:
- To highlight the significance of PET/CT in clinical oncology.
- To discuss the application of 18F-FDG PET/CT in staging, restaging, and treatment monitoring for diverse cancers.
- To emphasize the value of this integrated imaging approach in patient care.
Main Methods:
- Utilizes 18F-FDG PET/CT for imaging.
- Compares PET/CT findings with histopathology and other clinical data for validation.
- Integrates anatomical and metabolic information for comprehensive assessment.
Main Results:
- PET/CT is increasingly replacing separate PET and CT scans for oncologic indications.
- Numerous studies validate PET/CT findings using acceptable reference standards.
- The anatomo-metabolic information from PET/CT significantly impacts patient management.
Conclusions:
- PET/CT represents a major advancement in oncologic imaging.
- The integration of anatomical and metabolic data provides substantial benefits for cancer patients.
- The concept of "clinical oncology based on PET-CT" is justified by its clinical impact.
